GILD · 8-K · 20261029PR000037

Product Sales Performance

GILEAD SCIENCES, INC. · 2026-10-29 · Importance 64 · Surprise 56

Biktarvy sales increased 10% year over year to $4.059 billion, driven by higher demand, realized price and favorable inventory dynamics. Descovy sales rose 49% to $1.046 billion, primarily on higher realized price and favorable inventory dynamics. Livdelzi sales increased to $203 million from $105 million, and Trodelvy sales rose 42% to $506 million, both primarily reflecting higher demand. Yeztugo generated $305 million in third-quarter sales, compared with $39 million a year earlier.

Key facts

• Gilead’s third-quarter 2026 Biktarvy sales increased 10% to $4.1 billion year over year, driven primarily by higher demand, higher average realized price and favorable inventory dynamics. source